3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
13
Carcinoma, Hepatocellular
7
Carcinoma, Renal Cell
4
Lymphoma
3
Endometrial Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Lymphoma, Non-Hodgkin
2
Liver Neoplasms
2
Hodgkin Disease
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Breast Neoplasms
2
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Solid Tumor
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Interventions
pembrolizumab
11
Nivolumab
7
Sunitinib
6
Cyclophosphamide
6
aldesleukin
5
Sorafenib
5
Everolimus
5
temsirolimus
4
belzutifan
4
atezolizumab
4
Ipilimumab
4
fludarabine
3
cabozantinib
3
Interferon-alpha
3
Gene Expression Profiling
3
Fluorouracil
3
Docetaxel
3
Cetuximab
3
Busulfan
3
valspodar
2
sargramostim
2
perifosine
2
pazopanib
2
ixabepilone
2
entinostat
2
ciforadenant
2
belinostat
2
Thiotepa
2
Temozolomide
2
Sirolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Kidney Neoplasms
×
lenvatinib
×
Clear all
NCT05030506
2025-12-18
MK-6482-010
Merck Sharp & Dohme LLC
Phase 1
Active not recruiting
45 enrolled